SBTX vs. MRSN, NKTR, RVNC, NKTX, URGN, ADCT, ACIU, NLTX, VSTM, and KMDA
Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Mersana Therapeutics (MRSN), Nektar Therapeutics (NKTR), Revance Therapeutics (RVNC), Nkarta (NKTX), UroGen Pharma (URGN), ADC Therapeutics (ADCT), AC Immune (ACIU), Neoleukin Therapeutics (NLTX), Verastem (VSTM), and Kamada (KMDA). These companies are all part of the "pharmaceutical preparations" industry.
Silverback Therapeutics (NASDAQ:SBTX) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership.
74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Silverback Therapeutics has higher earnings, but lower revenue than Mersana Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
Mersana Therapeutics received 228 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 65.78% of users gave Mersana Therapeutics an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
Mersana Therapeutics has a consensus target price of $6.29, suggesting a potential upside of 161.90%. Given Mersana Therapeutics' higher probable upside, analysts plainly believe Mersana Therapeutics is more favorable than Silverback Therapeutics.
Silverback Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -352.01%. Silverback Therapeutics' return on equity of -29.62% beat Mersana Therapeutics' return on equity.
In the previous week, Mersana Therapeutics had 4 more articles in the media than Silverback Therapeutics. MarketBeat recorded 4 mentions for Mersana Therapeutics and 0 mentions for Silverback Therapeutics. Mersana Therapeutics' average media sentiment score of 1.26 beat Silverback Therapeutics' score of 0.00 indicating that Mersana Therapeutics is being referred to more favorably in the news media.
Summary
Mersana Therapeutics beats Silverback Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Silverback Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silverback Therapeutics Competitors List
Related Companies and Tools
